Encapsulating peritoneal sclerosis in liver transplant
Gabriel Melki; Abdalla Mohamed; Mina Fransawy Alkomos; Alisa Farokhian; Sohail M. Chaudhry; Varun Patel; Walid J. Baddoura
Abstract
Keywords
References
1 Cohen O, Abrahamson J, Ben-Ari J, Frajewicky V, Eldar S. Sclerosing encapsulating peritonitis. J Clin Gastroenterol. 1996;22(1):54-7.
2 Kawaguchi Y, Kwanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. Perit Dial Int. 2000;20(Suppl 4):S43-55.
3 Kawanishi H, Kawaguchi Y. Prevalence and therapeutic outcome of sclerosing encapsulatingperitonitis: A multicenter study in Japan. Jin To Toseki. 2000;49:225-8. In Japanese.
4 Mekeel K, Moss A, Reddy KS, Douglas D, Mulligan D. Sclerosing peritonitis and mortality after liver transplantation. Liver Transpl. 2009;15(4):435-9.
5 Maguire D, Srinivasan P, O’Grady J, Rela M, Heaton ND. Sclerosing encapsulating peritonitis after orthotopic liver transplantation. Am J Surg. 2001;182(2):151-4.
6 van Bommel EF, Hendriksz TF, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med. 2006;144(2):101-6.
7 Korte MR, Yo M, Betjes MG, et al. Increasing incidenceof sever encapsulating peritoneal sclerosis after kidney transplantation. Nephrol Dial Transplant. 2007;22(8):2412-4.
8 Korte MR, Fieren MW, Sampimon DE, Lingsma HF, Weimar W, Betjes MGHR. Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study. Nephrol Dial Transplant. 2011;26(2):691-7.
9 Balasubramaniam G, Brown EA, Davenport A, et al. The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant. 2009;24(10):3209-15.
Submitted date:
09/28/2020
Accepted date:
02/24/2021
Publication date:
05/06/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email